The human gene Ptpn11, which encodes the tyrosine phosphatase Shp2, may act as a proto-oncogene because dominantly activating mutations have been detected in several types of leukemia. Herein we report a tumor-suppressor function of Shp2. Hepatocyte-specific deletion of Shp2 promotes inflammatory signaling through the Stat3 pathway and hepatic inflammation/necrosis, resulting in regenerative hyperplasia and development of tumors in aged mice. Furthermore, Shp2 ablation dramatically enhanced diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) development, which was abolished by concurrent deletion of Shp2 and Stat3 in hepatocytes. Decreased Shp2 expression was detected in a subfraction of human HCC specimens. Thus, in contrast to the leukemogenic effect of dominant-active mutants, Ptpn11/Shp2 has a tumor-suppressor function in liver.
INTRODUCTION
The advancement in understanding the molecular basis of carcinogenesis has benefited tremendously from genetic and functional analyses of oncogenes and tumor-suppressor genes (Levine and Puzio-Kuter, 2010; Weinberg, 1995) . In conventional view the genesis of cancer can be triggered by dominant gain-of-function mutations in proto-oncogenes and recessive loss-of-function mutations in tumor-suppressor genes or antioncogenes (Bishop, 1991) . Studies initiated on v-Src and c-Src have revealed essential roles of tyrosine kinases in regulation of cell proliferation, and their oncogenic activation in promoting malignant transformation (Blume-Jensen and Hunter, 2001; Sefton and Hunter, 1986) . This conception has naturally predicted tyrosine phosphatases functioning as tumor suppressors. Indeed, genetic data have implicated loss or inactivation of tyrosine phosphatase genes in cancer development and metastasis (Revillion et al., 2009; Sun et al., 2011; Veeriah et al., 2009; Wang et al., 2004) .
Interestingly, recent work has led to identification of Ptpn11/ Shp2 as a proto-oncogene (Chan and Feng, 2007; Tartaglia et al., 2003) . Shp2 is an intracellular tyrosine phosphatase with two Src-homology 2 (SH2) domains that acts to promote activation of the Ras-Erk pathway by growth factors, cytokines, and hormones (Lai et al., 2004; Neel et al., 2003) . Autosomal-dominant mutations in the human gene Ptpn11 have been detected in nearly 50% of patients with Noonan syndrome who have higher risk of suffering juvenile myelomonocytic leukemia (JMML), and somatic mutations constitutively activating Shp2 have also been found in several types of leukemias (Tartaglia Significance Genetic and functional analyses of oncogenes and tumor suppressor genes have contributed tremendously to the rapid advance in understanding the molecular basis of carcinogenesis. Interestingly, the Ptpn11 gene that encodes the nonreceptor tyrosine phosphatase Shp2 has been identified as a proto-oncogene based on the detection of inherited and somatic dominant-active mutations of Ptpn11 in leukemias. However, data presented here suggest a tumor-inhibiting effect of Ptpn11/Shp2 in liver malignancy. Shp2 normally acts to suppress hepatocellular carcinogenesis via downregulation of inflammatory signaling. This study provides insight into the molecular mechanism linking inflammation and cancer.
and Gelb, 2005) . Overexpression of Shp2 was detected in leukemia and breast cancer cell lines and patient samples (Xu et al., 2005; Zhou et al., 2008) . In previous work we generated a hepatocyte-specific Shp2 knockout (Shp2 hepÀ/À ) mouse model, and found that Shp2 deletion suppressed Erk signal and hepatocyte proliferation following partial hepatectomy (Bard-Chapeau et al., 2006) . The effect of Shp2 in amplification of proliferative signal in hepatocytes is consistent with a body of literature documenting a positive role of this phosphatase in cellular responses to mitogenic stimuli (Lai et al., 2004; Neel et al., 2003) .
The present study is designed to investigate the possible tumor-suppressor function of Ptpn11/Shp2 in liver.
RESULTS

Shp2
hep-/-Mice Developed Hepatic Inflammation Figure S1A available online). There was also no difference between control and Shp2 hepÀ/À young mice in the ratio of liver weight to body weight ( Figure S1B ). Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly higher in Shp2 hepÀ/À mice than that in controls ( Figure 1A ).
Macroscopic examination revealed one or several foci of pallor noticeable on the liver surface in 34% of dissected Shp2 hepÀ/À animals (n = 21) ( Figure 1B ). Hematoxylin and eosin staining (H&E) of liver sections showed large areas of parenchymal necrosis ( Figure 1C ). Smaller focal areas of parenchymal necrosis were also detected ( Figures 1D and 1E ). Necrosis was observed in 47% of Shp2 hepÀ/À animals (n = 21) in contrast to 0% of control mice (n = 11). TUNEL assay revealed no significant difference in apoptosis between control and Shp2 hepÀ/À livers (data not shown). A large proportion (93%) of Shp2 hepÀ/À livers (n = 21) contained areas with infiltrate of inflammatory cells ( Figures 1D-1F ), which appeared to concentrate around the portal triads with extension into the parenchyma. Inflammatory cells were visible outside, around, or inside the necrotic areas. Necrotic zones were always associated with inflammatory cells ( Figures 1C-1E ), whereas inflammation was occasionally observed without necrosis ( Figure 1F ). Signs of fibrosis were found at the portal triads, but not near the necrosis or into parenchyma, as revealed by trichrome staining (Figures 1G and 1H) . We detected significantly increased amounts of circulating IL-6 in Shp2 hepÀ/À animals, among 11 cytokines examined ( Figure 1I ). We then examined local expression of cytokine and inflammatory genes in the liver by real-time RT-PCR ( Figure 1J ). Hepatic expression of IL-6, TNFa, and SAP (serum amyloid-P) mRNAs was remarkably elevated in Shp2 hepÀ/À livers, whereas transcripts of hepatocyte growth factor (HGF) and Bcl-xl were not changed ( Figure 1J ).
Enhanced Hepatic and Systemic Inflammatory Responses to LPS in Shp2 hep-/-Animals
To define hepatic inflammatory responses in Shp2 hepÀ/À mice,
we assessed induction of liver damage by lipopolysaccharides (LPS) challenge. Intraperitoneal LPS injection elicited a stronger liver damage response in Shp2 hepÀ/À mice than in controls, as indicated by higher serum ALT levels ( Figure 2A ). We also measured the ratio of spleen versus body weight to assess systemic inflammatory response. Shp2 hepÀ/À animals displayed an increase of 130% in their spleen size 14 days after LPS challenge as compared to 98% for control animals ( Figure 2B ), suggesting an aggravated immune/inflammatory response when Shp2 was removed in hepatocytes. H&E of liver sections also revealed increased inflammatory cell infiltration into hepatic parenchyma ( Figure 2C ). We measured circulating levels of inflammatory cytokines at different time points following LPS injection (Figures 2D and 2E) , and detected similarly increased levels for IFNg, RANTES, IL-12, IL-1b, and IL-10 in control and Shp2 hepÀ/À mice (Figure 2E) . However, higher levels of IL-6 and TNFa were detected in Shp2 hepÀ/À than in control mice after LPS injection, suggesting an enhanced IL-6 production in Shp2 hepÀ/À animals ( Figure 2D ).
Shp2 Deficiency in Hepatocytes Leads to Enhanced Inflammatory Signaling in the Liver
To dissect intracellular signaling events, we prepared liver extracts after LPS injection into vena cava for 5 min or intraperitoneally for longer time periods. LPS-stimulated pY-Stat3 and pY-Stat1 signals were increased and prolonged in Shp2 hepÀ/À liver compared to control ( Figures 3A and 3B ). Degradation of IkBa was potentiated at 1 hr after LPS challenge, p-Erk1/2 and p-p38 signals were impaired, whereas p-Jnk1/2 levels were elevated at 1 and 3 hr in mutant samples ( Figures 3A and 3B ).
To directly evaluate IL-6 signaling in the liver, we injected recombinant IL-6 through the portal vein ( Figure 3C only, due to cell type-specific Cre expression directed by the Albumin promoter. To determine the cell-intrinsic effect of Shp2 ablation, we isolated primary hepatocytes for treatment with LPS (5 mg/ml) in vitro. As shown in Figure 3D , Shp2 deletion had no effect on LPS stimulation of IkBa degradation (hence NF-kB activation) in hepatocytes. However, LPS-induced pY-Stat3 signal was enhanced and prolonged in Shp2-deficient hepatocytes. LPS-stimulated p-Erk and p-p38 signals were impaired, whereas p-Jnk levels were elevated in mutant, compared to control cells ( Figure 3D ). Akt was mildly stimulated by LPS in hepatocytes with higher basal and activated levels detected in mutants. Thus, Shp2 acts as a negative regulator for Stat3, Jnk, and Akt, while positively modulating Erk and p38 induction in hepatocytes by LPS ( Figure 3D ). (I) Circulating blood levels of inflammatory cytokines were quantified at 2-3 months of age (n = 7-18; *p < 0.05).
(J) Hepatic gene expression of IL-6, TNF, Bcl-xl, and HGF was assessed by qRT-PCR of total mRNAs isolated from 2-to 3-month-old mouse livers. The results were the average of three mice, and absolute mRNA values were determined and normalized to cyclophilin. Data were expressed as mean ± SEM. See also Figure S1 .
Consistently, pY-Stat3 signal was enhanced and sustained in Shp2 À/À hepatocytes following IL-6 treatment, whereas no significant change was detected for Stat1. IL-6-induced p-Erk and p-p38 levels were reduced, and p-Akt signal was elevated in mutant cells compared to controls ( Figure 3E ). We simultaneously measured LPS-induced cytokine secretion by hepatocytes in the culture medium ( Figure 3F ). LPS stimulation caused higher IL-6 secretion by Shp2-deficient hepatocytes, whereas comparable secretion levels were observed in control and mutant hepatocytes for several other cytokines, with mild increase of IL-12 and IL-10 detected at 24 hr of LPS stimulation ( Figure 3G ).
Shp2 Ablation Leads to Development of Hepatocellular Tumor in Aged Animals
We followed Shp2 hepÀ/À mice longitudinally to assess their phenotype later in life and detected efficient Shp2 deletion at 1 year of age (Figure 4A) . Aged Shp2 hepÀ/À mice became leaner by 10.7% for male and 14.9% for female mice, with a significant decrease of their body weights at 1 year ( Figure S2A ), although their livers were at normal size ( Figure S2B ). Beginning at 5 months of age, microscopic foci resembling regenerative foci were noticeable in the liver of Shp2 hepÀ/À animals. Nodular regenerative hyperplasia was detected in Shp2 hepÀ/À animals from 8 months of age. At 12-18 months of age, one or a few spherical macroscopic adenomas measuring 0.1-1 cm in diameter were frequently detected in Shp2 hepÀ/À mice (13 of 19) under both capsular and cut surface, which was not detectable in control animals (0 of 16). The tumors bulged from the liver surface and were often paler than the hepatic parenchyma ( Figure 4B ), but sometimes darker or red when accompanied by bleeding. On liver sections the tumors ). (E) Serum levels of IFNg, RANTES, IL-12, IL-1b, and IL-10 were quantified at indicated time points after LPS administration (n = 3-7). Data are expressed as mean ± SEM.
were unencapsulated, quite well delimited, showing expanding masses of hepatocytes, and positively stained with reticulin ( Figure 4C ).
The development of hepatocellular adenoma suggests increased and neoplastic proliferation of hepatocytes in the absence of Shp2, and we performed bromodeoxyuridine (BrdU) incorporation assay to quantify cell proliferation rate. BrdU + hepatocyte number was increased in Shp2 hepÀ/À animals as compared to littermate controls ( Figure 4D ). We found an average of 7.8% BrdU + cells in control animals (n = 5) versus 25.4% in the abnormal tissue of Shp2 hepÀ/À animals (n = 10), a significant increase of hepatocyte proliferation. Histological analysis of hepatic parenchyma revealed signs of regenerative hyperplasia with 13 of 19 Shp2 hepÀ/À livers having nodule formation ( Figures 4E-4G ). In most cases the lobular architecture was distorted by the development of hyperplastic hepatocyte plates ( Figures 4E-4G ). The space between hepatocytes was strikingly reduced inside the nodules ( Figure 4E ). TUNEL assay performed on liver sections revealed low number of apoptotic hepatocytes in Shp2 hepÀ/À liver parenchyma ( Figure 4H ). However, inside of or surrounding the hyperplastic nodules, massive hepatocyte degeneration was usually found, in association with vacuoles containing eosinophilic material (Figures 4G and 4H) . This explains the high levels of serum ALT and AST in 12-to 18-month-old Shp2 hepÀ/À mice despite the absence of hepatic necrosis at that age ( Figure 1A ). Although parenchymal necrosis and inflammation were not detected, aged mutant animals presented focal microgranuloma (8 of 19) consisting of mononuclear inflammatory cells ( Figure 4E ). To determine altered signaling events underlying development of hepatic adenoma in aged Shp2 hepÀ/À animals, we evaluated the activation status of several signaling molecules ( Figure 4I ). Elevated tyrosine phosphorylation levels of Stat3 were detected in two of four tumor samples. Efficient Shp2 deletion was steadily detected in adenoma cells, suggesting that escaped deletion of Shp2 flox/flox cells was not the cause of adenoma development/ progression in Shp2 hepÀ/À mice ( Figure 4I ). To explore the possible tumor-suppressing role of Shp2 in human hepatocellular carcinoma (HCC) development, we screened 104 HCC specimens for Shp2 expression and detected dramatically decreased Shp2 protein levels in HCC in 12 samples, as compared to their surrounding tissue ( Figure 4J ). This observation suggests that Shp2 deficiency is likely one of The phospho-signals were quantified and normalized against total liver protein amounts. IkBa protein amounts were normalized against Erk2 The relative signal levels were determined by setting the value of the control at 1 hr as 1 U (n = 3-6; *p < 0.05, **p < 0.01 for WT versus Shp2 hepÀ/À ). (C) Immunoblotting of liver lysates was performed 5 min after injection of IL-6 (5 mg) into portal vein. pY-Stat3 and pS-Stat3, and p-Erk levels were assessed. (D and E) pY-Stat3 and pS-Stat3, p-Jnk1/2, p-Akt (Ser473), p-Erk, p-p38 MAPK were assessed by immunoblot analysis with the respective protein levels as control. The IkBa degradation was compared to Erk2 protein level. (F and G) Amounts of inflammatory cytokines were quantified in supernatants from WT and Shp2 hepÀ/À hepatocytes (n = 3). Data are expressed as mean ± SEM.
the molecular mechanisms underlying initiation and/or progression of some human HCCs.
Stat3 Is Required for Promotion of HCC Development by Shp2 Deletion
To further determine the anti-oncogenic action of Shp2 in liver malignancy, we evaluated the effect of Shp2 removal on HCC in mice induced by chemical carcinogen. Control and Shp2 hepÀ/À mice were injected with a single dose of diethylnitrosamine (DEN) on postnatal day 15, and animals were dissected after 8 months to examine HCC incidences, as described previ- ously (He et al., 2010; Maeda et al., 2005) . All the male animals in both control and Shp2 hepÀ/À groups developed visible hepatic tumor foci ( Figure 5A ). However, hepatocytespecific deletion of Shp2 dramatically increased the number and sizes of liver tumors ( Figures  5A-5C ). We also used liver/body weight ratio to determine the tumor burden in DEN-treated animals. As shown in Figure 5D , the ratio increased almost 1-fold in Shp2 hepÀ/À animals, compared to controls. Consistent with the observation of spontaneous tumor development in aged Shp2 hepÀ/À mice, these results strongly support a notion that Shp2 is a tumor suppressor in HCCs elicited by chemical carcinogen.
We detected elevated pY-Stat3 levels in most of the tumor and surrounding tissues in Shp2 hepÀ/À livers, as compared to controls (Figure 5F ), suggesting constitutive activation of the Stat3 pathway in HCCs devoid of Shp2. This observation is also consistent with results shown in Figure 3 that Shp2 removal resulted in enhanced inflammatory signaling through Stat3. To determine the role of Stat3 in hepatocarcinogenesis enhanced by Shp2 deficiency, we generated hepatocyte-specific Shp2/Stat3 double knockout (DKO) mice and examined DEN-induced HCCs. Interestingly, simultaneous deletion of Shp2 and Stat3 in hepatocytes significantly suppressed the promoting effect of Shp2 ablation on HCC development ( Figures 5A-5E ). Although the tumor frequency and sizes were still higher in DKO than in control animals, there was no difference between DKO not prevent HCC occurrence, in contrast to a previous report (He et al., 2010) .
Tumors from both control and Stat3 hepÀ/À livers showed typical trabecular structure of HCC ( Figures 6A and 6D) and 6C ), and the inclusions in DKO tumors were much smaller ( Figure 6C ). H&E of liver tissues showed evident fat droplets in Stat3 hepÀ/À livers. Both Shp2 hepÀ/À and DKO animals exhibited significantly higher levels of serum ALT than controls, but ALT levels were lower in DKO animals than in Shp2 hepÀ/À animals (Figure 6I) . We also checked the hepatic inflammatory cytokines TNFa and IL-6, and levels of both cytokines were increased in Shp2 hepÀ/À livers, which was abolished by additional deletion of Stat3 ( Figures 6J and 6K ). This result was confirmed by qRT-PCR of IL-6 and TNFa transcripts ( Figures 6L and 6M ).
DISCUSSION
The results presented here indicate that selective deletion of Ptpn11/Shp2 in hepatocytes caused hepatic inflammation and necrosis, leading to nodular regenerative hyperplasia. The enhanced inflammatory signaling may have promoted liver tumorigenesis, resulting in dramatic increase of both spontaneous tumors and DEN-induced HCCs in Shp2 hepÀ/À mice. Consistent with the data obtained in the animal model, we also detected deficient/reduced Shp2 expression in 11.5% of human HCC samples. It will be interesting to determine whether there are deletion or point mutations at the Ptpn11/Shp2 locus in HCC genomes that could result in functional inactivation of this tyrosine phosphatase.
The tumor-suppressing role of Ptpn11/Shp2 in HCC is unexpected because our previous experiments indicated a positive role of Shp2 in regulation of hepatocyte proliferation and growth factor signaling through the Ras-Erk pathway by working in concert with Gab1 adaptor protein (Bard-Chapeau et al., 2006) . Furthermore, inherited or somatic mutations in human Ptpn11/Shp2 gene have been implicated in Noonan syndrome or several types of leukemias, particularly JMML, thus identifying Ptpn11 as a proto-oncogene (Chan and Feng, 2007; Tartaglia et al., 2006) . However, the inhibitory role of Shp2 on liver cancer is very similar to the dual function of the IKK/NF-kB pathway. Karin's group (Maeda et al., 2005) demonstrated an inhibitory effect of the IKKb/NF-kB pathway on DEN-induced HCC development, in contrast to its tumor-promoting effect in colitis-associated cancer (CAC) (Greten et al., 2004) . Deletion of NEMO/ IKKg also resulted in spontaneous development of HCC in mice (Luedde et al., 2007) . He et al. (2010) demonstrated further that deletion of IKKb in hepatocytes promoted HCC progression through upregulation of reactive oxidative stress (ROS).
Rapidly growing evidence reinforces the notion that tumors are promoted by inflammatory signals in the surrounding microenvironment (Coussens and Werb, 2002; Yu et al., 2007) . In this report we show that hepatocyte-specific deletion of Shp2 resulted in a marked increase of the inflammatory IL-6/Stat3 signal strength. Consistent with this observation is the previous work documented by us and others on a negative regulatory role of Shp2 in Jak-Stat signaling (Bard-Chapeau et al., 2006; Chan et al., 2003; Servidei et al., 1998; Wu et al., 2009; You et al., 1999) . Of note, we found that Shp2 ablation, while promoting IL-6-stimulated Stat3 activation, had no effect on IkBa degradation (NF-kB activation), suggesting that Shp2 acts downstream of, or in parallel with, NF-kB in modulation of Stat3 activity.
Indeed, a critical role of Stat3 in mediating inflammationprovoked malignancy has been reported in several types of cancer (He et al., 2010; Yu et al., 2009 ). It will be interesting to determine why and how Stat3 deletion also exacerbates hepatocarcinogenesis.
Because tumor incidence was increased in both Shp2 , previously called LSKO, liver-specific Shp2 knockout) mice (C57BL/6) were generated as previously described (Bard-Chapeau et al., 2006) . Shp2 flox/flox littermates were used as control mice. Genotyping was done by PCR analysis on genomic DNA extracted from mouse tails (Bard-Chapeau et al., 2006; Zhang et al., 2004) . Stat3 flox mice were reported previously (Alonzi et al., 2001) . Hepatocytespecific Shp2/Stat3 DKO mice were generated by crossing For chemical induction of hepatocarcinogenesis, mice at postnatal day 15 were injected intraperitoneally with DEN (25 mg/kg, N0258-1G; SigmaAldrich), and then weaned and maintained on regular chow food. Livers and tumors were pictured and harvested for analysis 8 months after the initial injection (He et al., 2010; Maeda et al., 2005) . All animals were housed in a virus-free facility and maintained in a temperature and light (12 hr light/dark cycle) controlled animal facility. Mice were permitted ad libitum access to water and standard chow. The SBMRI and UCSD Animal Use Committees approved all protocols.
Histology and Immunostaining
Liver fixation in paraffin and H&E of 5 mm sections were performed using standard protocols. The same slides were subjected to Masson's trichrome staining (Poly Scientific) or reticulin staining that was performed according to Gordon-Sweets Reticulum Procedure (Poly Scientific). TUNEL assay was conducted using ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon), and slides were counterstained with methyl green. Liver histology was examined by light microscopy in a blinded fashion. The extent of infiltration in parenchyma by inflammatory cells was semiquantitatively estimated by assigning a severity score (absent, 0; mild, 1; moderate, 2; pronounced, 3; severe, 4). This score was used to compare the liver damage and inflammation between control and Shp2 hepÀ/À mice after LPS challenge.
Aged animals drank 5-bromo-2 0 -deoxyuridine (BrdU, 1 mg/ml, SigmaAldrich, 1% sucrose, Sigma-Aldrich), and four mice in each group were sacrificed after 2 weeks. Withdrawn livers were prepared for 5 mm cryosectioning and immunostaining. BrdU labeling and detection Kit I were used to stain incorporated BrdU, and VECTASHIELD mounting medium with DAPI (Vector Laboratories) was used to stain nuclei. BrdU-positive hepatocytes were enumerated under fluorescent microscopy and calculated by randomly counting BrdU-stained nuclei per 100 DAPI + nuclei in a total of 2000 hepatocytes.
LPS or IL-6 Stimulation
Male animals (2-to 3-month-old littermates) were used. For 5 min stimulation a solution of LPS (1 mg/ml in PBS; Sigma-Aldrich) was injected into the vena cava at the dosage of 0.5 mg/25 g body weight, and livers were harvested and quickly frozen in liquid nitrogen. For later time points, 1, 3, 14, and 24 hr, 14 days, the same solution of LPS was injected intraperitoneally at a 4 mg/100 g body weight. Sera were collected at indicated time points, and livers were harvested for biochemistry and histology. Under anesthesia with Avertin (0.015 ml/g body weight), either 50 ml saline or 5 mg murine IL-6 (PeproTech Inc.) in 50 ml saline was injected into portal vein, and livers were harvested and quickly frozen 5 min later.
Serological and Biochemical Analyses
Venous blood was collected by bleeding of the retro-orbital sinus. Serum was separated after clotting. IL-6 and TNFa serum levels were determined by mouse Biotrak ELISA systems (Amersham Biosciences). ALT and AST levels in serum were measured by Animal Care Program, Diagnostic Laboratory, University of California, San Diego. Other inflammatory cytokine amounts in serum were assessed using Beadlyte Mouse Multi-Cytokine Detection System Kit from Upstate or a Meso Scale Discovery Assay. ELISA on liver extracts was performed as described previously (Cripps et al., 2010) . A total of 0.12 g/ml of liver tissue was homogenized in sucrose buffer (0.25 M sucrose, 10 mM Tris [pH 7.4], protease inhibitor cocktail) and cleared by centrifugation (9300 3 g, 10 min). Frozen tissue samples were processed as previously described (BardChapeau et al., 2006) . Homemade antibody against Shp2 was described previously (Feng et al., 1993 
Statistical Analysis
Data analysis was performed using a two-tailed unpaired Student's t test.
Values are expressed as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
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